Back to Search Start Over

Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation.

Authors :
Xu, Jianlin
Yang, Haitang
Jin, Bo
Lou, Yuqing
Zhang, Yanwei
Zhang, Xueyan
Zhong, Hua
Wang, Huiming
Wu, Dan
Han, Baohui
Source :
Scientific Reports. 12/2/2016, p38270. 1p.
Publication Year :
2016

Details

Language :
English
ISSN :
20452322
Database :
Academic Search Index
Journal :
Scientific Reports
Publication Type :
Academic Journal
Accession number :
119939936
Full Text :
https://doi.org/10.1038/srep38270